Abstract

Ventricular fibrillation (VF) and sudden cardiac death (SCD) are predominantly caused by channelopathies and cardiomyopathies in youngsters and coronary heart disease in the elderly. Temporary factors, e.g., electrolyte imbalance, drug interactions, and substance abuses may play an additive role in arrhythmogenesis. Ectopic automaticity, triggered activity, and reentry mechanisms are known as important electrophysiological substrates for VF determining the antiarrhythmic therapies at the same time. Emergency need for electrical cardioversion is supported by the fact that every minute without defibrillation decreases survival rates by approximately 7%–10%. Thus, early defibrillation is an essential part of antiarrhythmic emergency management. Drug therapy has its relevance rather in the prevention of sudden cardiac death, where early recognition and treatment of the underlying disease has significant importance. Cardioprotective and antiarrhythmic effects of beta blockers in patients predisposed to sudden cardiac death were highlighted in numerous studies, hence nowadays these drugs are considered to be the cornerstones of the prevention and treatment of life-threatening ventricular arrhythmias. Nevertheless, other medical therapies have not been proven to be useful in the prevention of VF. Although amiodarone has shown positive results occasionally, this was not demonstrated to be consistent. Furthermore, the potential proarrhythmic effects of drugs may also limit their applicability. Based on these unfavorable observations we highlight the importance of arrhythmia prevention, where echocardiography, electrocardiography and laboratory testing play a significant role even in the emergency setting. In the following we provide a summary on the latest developments on cardiopulmonary resuscitation, and the evaluation and preventive treatment possibilities of patients with increased susceptibility to VF and SCD.

Highlights

  • Ventricular fibrillation (VF) is an emergency condition that, without immediate treatment, leads to death

  • Cardioprotective and antiarrhythmic effects of beta blockers in patients predisposed to sudden cardiac death were highlighted in numerous studies, nowadays these drugs are considered to be the cornerstones of the prevention and treatment of life-threatening ventricular arrhythmias

  • In the following we provide a summary on the latest developments on cardiopulmonary resuscitation, and the evaluation and preventive treatment possibilities of patients with increased susceptibility to VF and sudden cardiac death (SCD)

Read more

Summary

Handling of Ventricular Fibrillation in the Emergency Setting

Zoltán Szabó1*, Dóra Ujvárosy, Tamás Ötvös, Veronika Sebestyén and Péter P. Ventricular fibrillation (VF) and sudden cardiac death (SCD) are predominantly caused by channelopathies and cardiomyopathies in youngsters and coronary heart disease in the elderly. Drug therapy has its relevance rather in the prevention of sudden cardiac death, where early recognition and treatment of the underlying disease has significant importance. Cardioprotective and antiarrhythmic effects of beta blockers in patients predisposed to sudden cardiac death were highlighted in numerous studies, nowadays these drugs are considered to be the cornerstones of the prevention and treatment of life-threatening ventricular arrhythmias. The potential proarrhythmic effects of drugs may limit their applicability. Based on these unfavorable observations we highlight the importance of arrhythmia prevention, where echocardiography, electrocardiography and laboratory testing play a significant role even in the emergency setting.

INTRODUCTION
Handling of Ventricular Fibrillation
PATHOLOGICAL CONDITIONS UNDERLYING VENTRICULAR FIBRILLATION
TEMPORARY CAUSES long QT syndrome short QT syndrome
RISK ASSESSMENT OF VENTRICULAR FIBRILLATION
Laboratory Opportunities for Predicting Ventricular Arrhythmias
Estimating Arrhythmia Susceptibility With Imaging Methods
Electrocardiographic Estimation of the Risk for Ventricular Arrhythmias
THE TREATMENT OF VENTRICULAR FIBRILLATION
CHEST COMPRESSION DEVICES
CLINICAL FACTORS AFFECTING THE OUTCOME OF RESUSCITATION
DRUG THERAPY DURING RESUSCITATION
CONSIDERATIONS FOR THE TREATMENT OF REFRACTORY VENTRICULAR FIBRILLATION
ABLATION OF VF TRIGGERS AND SUBSTRATES
Findings
SUMMARY

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.